Dipeptidyl Peptidase 1 (DPP-1) Inhibitors for Bronchiectasis - Overview and Q & A

On August 12, 2025 the US Food and Drug Administration (FDA) approved the first treatment for non-cystic fibrosis bronchiectasis, a DPP-1 inhibitor. Dr. Anne O'Donnell of Medstar Georgetown gives an overview of bronchiectasis, discusses how DPP1 inhibitors work, and reviews the recent studies. She then answers questions about the new, novel drug.